Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

Hong Ying Huang, Shahrokh F. Shariat, Tung Tien Sun, Herbert Lepor, Ellen Shapiro, Jer-Tsong Hsieh, Raheela Ashfaq, Yair Lotan, Xue Ru Wu

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.

Original languageEnglish (US)
Pages (from-to)1703-1713
Number of pages11
JournalHuman Pathology
Volume38
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Uroplakins
Carcinoma
Neoplasms
Urinary Bladder
Lymph Nodes
Neoplasm Metastasis
Recurrence
Urothelium
Neoplastic Stem Cells
Mortality
Cystectomy
Cyclin D1

Keywords

  • Bladder cancer
  • Prognosis
  • Progression
  • Transitional cell carcinoma
  • Uroplakin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Persistent uroplakin expression in advanced urothelial carcinomas : implications in urothelial tumor progression and clinical outcome. / Huang, Hong Ying; Shariat, Shahrokh F.; Sun, Tung Tien; Lepor, Herbert; Shapiro, Ellen; Hsieh, Jer-Tsong; Ashfaq, Raheela; Lotan, Yair; Wu, Xue Ru.

In: Human Pathology, Vol. 38, No. 11, 11.2007, p. 1703-1713.

Research output: Contribution to journalArticle

Huang, Hong Ying ; Shariat, Shahrokh F. ; Sun, Tung Tien ; Lepor, Herbert ; Shapiro, Ellen ; Hsieh, Jer-Tsong ; Ashfaq, Raheela ; Lotan, Yair ; Wu, Xue Ru. / Persistent uroplakin expression in advanced urothelial carcinomas : implications in urothelial tumor progression and clinical outcome. In: Human Pathology. 2007 ; Vol. 38, No. 11. pp. 1703-1713.
@article{0df7bdc0c1d84353adfe0d8b9c96bd59,
title = "Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome",
abstract = "As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85{\%}) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5{\%}) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66{\%}) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.",
keywords = "Bladder cancer, Prognosis, Progression, Transitional cell carcinoma, Uroplakin",
author = "Huang, {Hong Ying} and Shariat, {Shahrokh F.} and Sun, {Tung Tien} and Herbert Lepor and Ellen Shapiro and Jer-Tsong Hsieh and Raheela Ashfaq and Yair Lotan and Wu, {Xue Ru}",
year = "2007",
month = "11",
doi = "10.1016/j.humpath.2007.04.003",
language = "English (US)",
volume = "38",
pages = "1703--1713",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Persistent uroplakin expression in advanced urothelial carcinomas

T2 - implications in urothelial tumor progression and clinical outcome

AU - Huang, Hong Ying

AU - Shariat, Shahrokh F.

AU - Sun, Tung Tien

AU - Lepor, Herbert

AU - Shapiro, Ellen

AU - Hsieh, Jer-Tsong

AU - Ashfaq, Raheela

AU - Lotan, Yair

AU - Wu, Xue Ru

PY - 2007/11

Y1 - 2007/11

N2 - As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.

AB - As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.

KW - Bladder cancer

KW - Prognosis

KW - Progression

KW - Transitional cell carcinoma

KW - Uroplakin

UR - http://www.scopus.com/inward/record.url?scp=35348887132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348887132&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2007.04.003

DO - 10.1016/j.humpath.2007.04.003

M3 - Article

C2 - 17707461

AN - SCOPUS:35348887132

VL - 38

SP - 1703

EP - 1713

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -